DDInter1717 DDInter1082
Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances [A177655, F4519]. Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Sucralfate {u} (Compound) binds {v} (Gene) FGF2
Sucralfate {u} (Compound) is included by {v} (Pharmacologic Class) Organometallic Compounds
Sucralfate {u} (Compound) causes {v} (Side Effect) Haemolysis
Sucralfate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sotalol
Sucralfate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Sucralfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Sucralfate {u} may lead to a major life threatening interaction when taken with {v} Dolutegravir
Sucralfate (Compound) binds FGF2 (Gene)
Sucralfate (Compound) is included by Organometallic Compounds (Pharmacologic Class)
Sucralfate (Compound) causes Haemolysis (Side Effect)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Sotalol
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Theophylline
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Acarbose
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Sucralfate may lead to a major life threatening interaction when taken with Dolutegravir